An observational study in Myasthenia Gravis, sponsored by Vitaccess Ltd. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.
Sponsored by Vitaccess Ltd · Observational
Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.
Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 13th largest by planned enrollment of the 36 observational ones that give a count, is one of 23 that started in 2024, is one of 36 observational ones, reaches primary completion later than 68 of the 72 other live ones, and was the 89th registered.
330 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
George Washington University · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Brazil and 5 more countries
Ages 2–17
argenx · Sites in United States, Belgium, Greece and 3 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 38 · Phase 3 51 · Phase 4 3
First in 1995; this study’s year is marked. 23 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 130 across 105 observational studies indexed under Myasthenia Gravis.
Median enrollment 56 across the 108 interventional studies, 226 across the 36 observational. Of the 64 that completed or were terminated, 41 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 144 have an industry lead sponsor. The 10 most frequent:
Vitaccess Ltd is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Vitaccess Ltd has 2 studies filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
18 of the studies in Myasthenia Gravis with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06799247Phase 3Cartesian TherapeuticsInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | 2026-12-30 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 144 studies in Myasthenia Gravis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 600 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from medical records.
Patients will be recruited at clinical sites in all participating countries. In the US only, patients can additionally be recruited via community neurologists or direct-to-patient recruitment.
Traditional site recruitment (all countries):
Adult patients who are being treated for MG at one of the participating clinics or centers in one of the participating countries (currently the US and UK) at the time of enrolment and who meet the inclusion and exclusion criteria will be identified and approached by their clinical team and invited to participate in the registry.
Patient-reported data will be collected via the VRMG Registry platform, a digital data capture platform accessible via any web-enabled platform (e.g., phone, tablet, laptop, computer). Custom survey and patient-reported outcomes data will be collected at baseline and at regular intervals thereafter for a follow-up period of up to 10 years. The data collected will capture the impact of MG on daily living, fatigue, and health-related quality of life.
Site research teams will complete and update an eCRF (every six months ± one months) for each patient, including data from the patient's EMR. eCRFs that are completed within one months prior to or following each six-month mark will be considered within the same assessment window for analytics purposes so that patients will not be required to visit the clinical site for the purposes of the registry outside of their regular clinical visits.
Community neurologist recruitment (US only):
Community neurologists who are treating MG patients who would be eligible for participation in the registry will be able to register their interest for involvement and provide details of their credentials via an informational website. Approved community neurologists will identify and approach potential participants, who will participate in the registry as normal. Clinical data will be captured from participants' electronic medical records via an EMR aggregator.
Direct-to-patient recruitment (US only):
A cohort of US-based participants in the MyRealWorld MG study - a longitudinal observational study in MG that Vitaccess has run since 2019 - have provided consent to be contacted by Vitaccess about future research. Vitaccess will contact this patient cohort directly via email to introduce them to the registry; patients can access the registry's informational website to get further information. Clinical data will be captured from participants' electronic medical records via an EMR aggregator.
Patient-reported and eCRF data will be linked via a unique ID and PIN assigned to each participant at enrolment.
Adult patients who are being treated for MG at one of the participating clinics or centers in one of the study countries at the time of enrolment and who meet the inclusion and exclusion criteria will be identified and approached by their clinical team and invited to participate in the registry.
Adult patients in the US who are not being treated at a participating clinic will be able to enrol via their community neurologist or direct-to-patient recruitment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Vitaccess Real MG Registry
A patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life.
Time frame: 10 years
Describe the demographic characteristics of patients
EMR data reported by HCPs or captured via EMR aggregator ("Registration Form")
Time frame: At baseline
Describe change in clinical trial participation of patients
EMR data reported by HCPs or captured via EMR aggregator ("Clinical Trial Participation Form")
Time frame: At follow-up visits (every 6±1 months) for up to 10 years
Describe the diagnosis (date, tests, and symptoms) of patients
EMR data reported by HCPs or captured via EMR aggregator ("Diagnosis Information Form")
Time frame: At baseline
Describe change in clinical characteristics of patients.
EMR data reported by HCPs or captured via EMR aggregator ("Clinical Characteristics Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
Describe change in medical history of patients
EMR data reported by HCPs or captured via EMR aggregator ("Medical History Form")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
Describe change in concomitant treatments received by patients
EMR data reported by HCPs or captured via EMR aggregator ("Concomitant Medication Log")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
Describe change in routine MG treatments received by patients
EMR data reported by HCPs or captured via EMR aggregator ("Routine MG Treatments Log")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
Describe change in rescue MG treatments received by patients
EMR data reported by HCPs or captured via EMR aggregator ("Rescue MG Treatments Log")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
Describe change in severity of MG symptoms experienced by patients
Myasthenia Gravis Activities of Daily Living (MG-ADL) data reported by HCPs or captured via EMR aggregator ("MG-ADL")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
Describe change in healthcare resource use of patients
EMR data reported by HCPs or captured via EMR aggregator ("Healthcare Resource Use")
Time frame: At baseline visit and at follow-up visits (every 6±1 months) for up to 10 years
Describe change in type and severity of adverse events experienced by patients
EMR data reported by HCPs or captured via EMR aggregator ("Adverse Events")
Time frame: At follow-up visits (every 6±1 months) for up to 10 years
Describe change in severity of MG symptoms experienced by patients
Myasthenia Gravis Activities of Daily Living (MG-ADL) data reported by patients via the Vitaccess Real MG Registry platform ("MG-ADL")
Time frame: At baseline and every 1 month thereafter for up to 10 years.
Describe change in type and severity of fatigue experienced by patients
MG Symptoms PRO Fatigue Component data reported by patients via the Vitaccess Real MG Registry platform ("MG Symptoms PRO Fatigue Component")
Time frame: At baseline and every 2 months thereafter for up to 10 years.
Describe change in type and severity of fatigue experienced by patients
NeuroQoL Fatigue Short Form data reported by patients via the Vitaccess Real MG Registry platform ("NeuroQoL Fatigue Short Form")
Time frame: At baseline and every 2 months thereafter for up to 10 years.
Describe change in impact of MG on health-related quality of life of patients
Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL-15r) data reported by patients via the Vitaccess Real MG Registry platform ("MG-QoL-15r")
Time frame: At baseline and every 2 months thereafter for up to 10 years.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jul 2034, 120 months after the start.
Of 62 observational studies under Myasthenia Gravis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24. This study's planned 120 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vitaccess Ltd